2024
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian age
2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptoms
2021
Genetic testing documentation in survivorship care plans in patients with breast cancer.
Kaur K, Shinde N, Klemanski D, Xu M, Aeilts A, Lustberg M, Jeter J. Genetic testing documentation in survivorship care plans in patients with breast cancer. Journal Of Clinical Oncology 2021, 39: e24110-e24110. DOI: 10.1200/jco.2021.39.15_suppl.e24110.Peer-Reviewed Original ResearchSurvivorship care plansGenetic testing resultsSCP templatesGenetic testingBreast cancerCare plansResult groupGermline mutationsRetrospective chart reviewBreast cancer patientsTest result groupOncology treatment teamNon-Hispanic whitesExtent of documentationCancer genetic testingGenetic counselorsSurvivorship visitChart reviewMedian ageCancer survivorsCancer patientsResult categoriesInvolved genesHereditary predispositionTreatment teamPhase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline group
2020
Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.
Johns K, Kalister S, Mwandha N, Adams E, Basinger H, Fugett S, Crawford D, Draime M, Shinde N, Kassem M, Radcliff L, Unthank B, Cherian M, Sardesai S, Stover D, Vandeusen J, Wesolowski R, Williams N, Ramaswamy B, Lustberg M. Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients. Journal Of Clinical Oncology 2020, 38: e14004-e14004. DOI: 10.1200/jco.2020.38.15_suppl.e14004.Peer-Reviewed Original ResearchCollaborative care modelPHQ-9 scoresCare modelCancer patientsPHQ-9Satisfaction scoresAverage patient satisfaction scoreRegular case reviewBreast cancer patientsPatient satisfaction scoresGAD-7 scoresInitial scoresMental health servicesMental health careMental health resourcesTeam-based modelForms of cancerEndocrine therapyClinical suspicionExcess morbidityMedian ageMedical oncologistsBC patientsCDK4/6 inhibitorsCancer population
2019
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
Williams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalPrimary cancerOhio State University Comprehensive Cancer CenterSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologySolid tumor malignanciesConfirmation of diagnosisComprehensive cancer centerClinical characteristicsMedian ageMRI findingsInitial diagnosis
2017
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.
Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.Peer-Reviewed Original ResearchNeo-adjuvant chemotherapyCD8 T cellsCD4 T cellsMore CD8 T cellsT cellsBreast cancerReceptor expressionCheckpoint inhibitorsCheckpoint expressionComplete pathologic response rateMore CD4 T cellsHormone receptorsPathologic response rateClinical stage IOperable breast cancerImmune checkpoint expressionReceptor expression changesBC subgroupsNeoadjuvant chemotherapyClinical responseProspective trialImmune checkpointsMedian agePD-1CTLA-4
2015
Effects of chemotherapy on quality of life in breast cancer survivors.
Wandell K, Lustberg M, Reinbolt R, Orchard T, Andridge R, Wandell H, Schade C, Moran T, Yang N, Conlan T. Effects of chemotherapy on quality of life in breast cancer survivors. Journal Of Clinical Oncology 2015, 33: 112-112. DOI: 10.1200/jco.2015.33.28_suppl.112.Peer-Reviewed Original ResearchBody mass indexDuke Activity Status IndexQuality of lifeInitiation of treatmentBreast cancer survivorsNutrition-related symptomsFunctional statusCancer survivorsFunctional capacityFirst cycle chemotherapyPG-SGA scoreSubjective Global AssessmentPatients' functional statusDuration of chemotherapyEffect of chemotherapyPeak oxygen uptakeCycle chemotherapyPG-SGAAdjuvant therapySymptom burdenMedian ageMass indexPoor outcomeSignificant changesBreast cancer